Compare Cytokinetics Inc (CYTK) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Flux Power Holdings Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Flux Power Holdings Inc trades at $0.46 (market cap $9.97M). The key difference: Cytokinetics Inc is far larger — about 864.6× Flux Power Holdings Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Flux Power Holdings Inc for 20 Days on average.
| CYTK | FLUX | |
|---|---|---|
Market Cap | $8.62B | $9.97M |
Volume | 2,594,626 | 817,320 |
Sector | Health | Industrials |
52-Week High | $87.26 | $6.66 |
52-Week Low | $54.76 | $0.41 |
Typical Hold Time | 19 Days | 20 Days |
Enterprise Value | $8.72B | $18.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
FLUX trades at $0.4612, down 5.92% today, with a bearish technical signal despite unanimous analyst buy ratings. The company reported declining revenue from $66M in 2025 to $42M in 2026 while maintaining a net loss of -$7M. Recent news highlights a rejected acquisition offer from Solidion Technology, creating uncertainty around strategic direction.
The stock faces fundamental challenges with negative profitability metrics but maintains a low P/S ratio of 0.22. Investment opportunity exists if operational improvements materialize, while risks include persistent losses and acquisition-related volatility. Analyst consensus remains optimistic with 6 buy ratings despite recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
